Getinge B stock rises 2.35 percent as analyst caution returns
Published on 09/28/2026 at 10:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Getinge B stock (ISIN SE0000202624) was trading at SEK 248.60 on Nasdaq Stockholm on September 28, 2026, up 2.35 percent from the previous close of SEK 242.90. The move comes after BorsKollen reported on September 24, 2026, that Pareto Securities downgraded Getinge from Buy to Hold while repeating its SEK 255.00 price target.
Pareto sees limited valuation room
Pareto's target lies 2.57 percent above the September 28 price. The research house expects 2026 organic sales growth of 2.5 percent, below Getinge's guidance range of 3 percent to 5 percent, and said the shares traded at an 11 percent to 13 percent premium to European medical technology peers.
That comparison makes the next earnings update important. Getinge's Q3 performance will need to show that margin recovery is advancing faster than the valuation already reflects, especially after the stock's 2026 move to SEK 248.60.
Q2 delivered stronger operating metrics
In its Q2 2026 earnings call, Yahoo Finance reported that Getinge achieved 4.6 percent organic net sales growth and 6.2 percent organic order intake growth in the quarter ended June 30, 2026. Adjusted EBITA reached SEK 1.478 billion, equal to a 17.6 percent margin.
The same Q2 discussion showed both progress and pressure. Free cash flow reached SEK 1.0 billion, while financial leverage stood at 1.7 times adjusted EBITA against an internal threshold of 2.5 times. Getinge also reiterated its 2026 organic net sales growth guidance of 3 percent to 5 percent.
Stock remains near its yearly high
At SEK 248.60 on September 28, Getinge B stood 0.16 percent below its 52-week high of SEK 249.00 and 41.33 percent above its 52-week low of SEK 175.90. The session volume was 81,803 shares, while market capitalization stood at SEK 67.7 billion.
For investors, the central tension is measurable: Q2 growth and profitability improved, but Pareto's 2.5 percent 2026 growth estimate sits below company guidance and its SEK 255.00 target offers limited distance above the market price.
Getinge B stock data
- Company: Getinge AB (publ)
- ISIN: SE0000202624
- WKN: 889714
- Ticker: GETI B
- Trading venue: Nasdaq Stockholm
- Price (as of September 28, 2026, 10:33 a.m. CEST): SEK 248.60
- Market capitalization: SEK 67.7 billion (as of September 28, 2026)
- 52-week range: SEK 175.90-249.00 (as of September 28, 2026)
- Sector / Industry: Healthcare / Medical Equipment, Supplies and Distribution
